• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Infinant Health Appoints New Team Members to assist with Drug Development

    5/22/24 6:13:00 AM ET
    $BDC
    Telecommunications Equipment
    Industrials
    Get the next $BDC alert in real time by email

    DAVIS, Calif., May 22, 2024 /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health by supporting the development and restoration of the immune system via the gut microbiome, announces additions to their advisory team: Dr. Katharine Knobil and Dr. David Pompliano. Additionally, Judy Gawlik Brown has joined the board, representing Manna Tree Partners, to help prepare the company's expansion into pharma. 

    Infinant Health logo (PRNewsfoto/Infinant Health)

    Infinant Health recently announced their submission for ODD status and are augmenting their team with top-tier experts to support work underway on their groundbreaking product Bifidobacterium longum subspecies infantis strain, INF108, aimed at averting necrotizing enterocolitis (NEC) in premature infants.

    "It is with great pleasure that I announce the addition of three distinguished individuals to our team at Infinant Health. The extensive expertise they bring in human clinical trials, coupled with their profound pharmaceutical knowledge, fortifies our resolve as we embark on the next pivotal phase of our company's evolution," stated CEO Mike Johnson. He continued, "This strategic move underscores our commitment to pioneering advancements in the microbiome space and our dedication to excellence in therapeutic product development."

    Katharine Knobil, MD

    Dr. Knobil has been appointed as an Advisor to the Infinant Health Board, bringing more than 25 years of experience in pharmaceutical research and product development including global clinical research, medical affairs and patient safety in large pharma, biotech, and medtech. Dr. Knobil has strategically led research and development resulting in regulatory approval and the successful launch of blockbuster medicines.

    Dr. Knobil was the first Chief Medical Officer at Agilent Technologies, the Chief Medical Officer and Head of Research and Development at Kaleido Biosciences, and Chief Medical Officer at GlaxoSmithKline. At GSK, she directed the development of multiple new chemical entities and product line extensions, including Flolan for Primary Pulmonary Hypertension and Advair for COPD. She held roles both domestically and in expat assignments in London and Shanghai, where she established the GSK clinical development organization in China. During her career, Kate led the development and delivery of presentations at regulatory agencies worldwide, including multiple FDA Advisory Committees. Dr. Knobil currently serves on the boards of Pliant Therapeutics, Inc., Marker Therapeutics, Inc., and Nimbus Therapeutics, LLC. 

    Dr. Knobil earned a BA in Biology from Cornell University, her Doctor of Medicine degree from The University of Texas Southwestern Medical School, completed her internal medicine residency at the University of Michigan Medical School, and completed her fellowship in pulmonary and critical care medicine at Johns Hopkins University School of Medicine. 

    David Pompliano, PhD

    Dr. Pompliano has been appointed as an Advisor to the Infinant Health Board, offering his expertise in the pharmaceutical space as the company progresses along the pharmaceutical development path. Dr. Pompliano is a drug discovery scientist, entrepreneur and executive with >30 years of experience in the biopharmaceutical industry. Working with venture-capitalists and academicians, he creates scientifically precocious, game-changing new commercial enterprises based on exciting discoveries in academic science. 

    Dr. Pompliano co-founded, and served as CSO, CIO or CEO of, Odyssey Therapeutics, Daros, Lodo Therapeutics (acquired by Zymergen) and Revolution Medicines (RVMD), and helped raise over $400m in Series A financing. He is currently co-founder and CEO of Donum Therapeutics. Earlier, as a senior executive at GlaxoSmithKline and Merck, he led drug discovery teams that produced pre-clinical credentials for >30 development candidates and five registered anti-infective (Recarbrio, Altabax) and oncology (Tykerb, Votrient, Promacta) drugs. As Owner of Sanderling Consulting LLC, he assists investors, companies, and philanthropies in setting drug discovery strategy, in executing the operations of preclinical discovery and development, and in evaluating pharmaceutical assets.

    Dr. Pompliano earned the BS and PhD degrees in Chemistry from the University of Virginia and from Stanford University, respectively, and conducted research in enzymology and molecular biology as a National Institutes of Health Postdoctoral Fellow in Jeremy Knowles' laboratory at Harvard University. He has published more than 50 peer-reviewed papers in the areas of infectious diseases, cancer drug discovery, and mechanistic enzymology.

    Judy Gawlik Brown, MBA

    Judy Gawlik Brown has agreed to be a Member of the Board of Directors for Infinant Health, representing Manna Tree Partners. She brings a wealth of knowledge from her experience in the pharmaceutical and consumer healthcare industries.

    Ms. Brown held various executive roles at global biotechnology leader Amgen, most recently as SVP of corporate affairs, responsible for strategic communications, patient advocacy, ESG strategies, and implementation. Prior to that role, she served as SVP global business solutions and finance, responsible for the global business solutions, global internal audit, tax, and treasury organizations.

    Before joining Amgen, Ms. Brown served as EVP of business operations and CFO at Perrigo Company, where she oversaw all financial operations as well as IT, government affairs, corporate communications, shared services, M&A and strategy for over a decade. During her tenure, she was regularly recognized as a leading finance executive by Institutional Investor, the Wall Street Journal and IR Magazine.

    Ms. Brown is a Certified Public Accountant and received her MBA from the University of Chicago and a BS in accountancy from the University of Illinois at Urbana-Champaign. She is a board director of Belden Corporation (NYSE:BDC) where she is a member of the Audit Committee and Chair of the Finance Committee.

    ABOUT INFINANT HEALTH, INC

    Infinant Health, Inc ("Infinant Health"), previously known as Evolve Biosystems, is a privately held company committed to changing the trajectory of human health by supporting the development of the immune system via the gut microbiome. Investors in the company include the Bill and Melinda Gates Foundation, Johnson & Johnson, Cargill, and other leading institutions. Learn more about Infinant Health at www.infinanthealth.com.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/infinant-health-appoints-new-team-members-to-assist-with-drug-development-302151985.html

    SOURCE Infinant Health

    Get the next $BDC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDC

    DatePrice TargetRatingAnalyst
    7/23/2024$110.00Buy
    Vertical Research
    10/13/2023Overweight → Equal Weight
    Fox Advisors
    9/27/2023$115.00Buy
    UBS
    9/5/2023$93.00 → $117.00Neutral → Buy
    Goldman
    11/22/2022$86.00Hold
    Jefferies
    4/20/2022$57.00 → $55.00Sell → Neutral
    Goldman
    9/9/2021$53.00 → $68.00Hold → Buy
    Canaccord Genuity
    8/6/2021$39.00 → $46.00Sell
    Goldman Sachs
    More analyst ratings

    $BDC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Belden Inc

      10-Q - BELDEN INC. (0000913142) (Filer)

      5/1/25 12:03:18 PM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • Belden Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BELDEN INC. (0000913142) (Filer)

      5/1/25 7:50:13 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • SEC Form DEF 14A filed by Belden Inc

      DEF 14A - BELDEN INC. (0000913142) (Filer)

      4/8/25 4:54:34 PM ET
      $BDC
      Telecommunications Equipment
      Industrials

    $BDC
    Financials

    Live finance-specific insights

    See more
    • Belden Reports First Quarter 2025 Results

      Belden Inc. (NYSE:BDC) ("Belden" or the "Company"), a leading global supplier of complete connection solutions, today reported fiscal first quarter results for the period ended March 30, 2025. First Quarter 2025 Highlights Revenues of $625 million, up 17% y/y and up 11% y/y organically GAAP EPS of $1.27, up 41% y/y Adjusted EPS of $1.60, up 29% y/y Repurchased 0.8 million shares for $85 million during the quarter, and 1.0 million shares for $100 million year-to-date through April 30, 2025 "Thanks to the efforts of our team, Belden had a strong start to the year with revenues up 17%, combined with expanding margins," said Ashish Chand, President and CEO of Belden. "Demand remains

      5/1/25 7:30:00 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • Belden to Announce First Quarter 2025 Results

      Belden Inc. (NYSE:BDC), a leading global supplier of complete connection solutions, will report its fiscal first quarter results for the period ended March 30, 2025, before the market opens on Thursday, May 1, 2025. Management will discuss the Company's results during a conference call at 8:30 a.m. Eastern Time. A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Belden's corporate website at https://investor.belden.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register and download and install any necessary audio software. To participate in th

      4/10/25 9:00:00 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • Belden Declares Quarterly Dividend

      The Board of Directors of Belden Inc. (NYSE:BDC) today declared a quarterly dividend to holders of common stock of $0.05 per share payable on April 10, 2025, to shareholders of record as of March 13, 2025. About Belden Belden Inc. delivers complete connection solutions that unlock untold possibilities for our customers, their customers and the world. We advance ideas and technologies that enable a safer, smarter and more prosperous future. Throughout our 120+ year history we have evolved as a company, but our purpose remains – making connections. By connecting people, information and ideas, we make it possible. We are headquartered in St. Louis and have manufacturing capabilities in North

      2/27/25 4:05:00 PM ET
      $BDC
      Telecommunications Equipment
      Industrials

    $BDC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BDC
    Leadership Updates

    Live Leadership Updates

    See more

    $BDC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BDC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tate Leah bought $100,022 worth of shares (1,550 units at $64.53) (SEC Form 4)

      4 - BELDEN INC. (0000913142) (Issuer)

      11/13/23 1:50:15 PM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • Infinant Health Appoints New Team Members to assist with Drug Development

      DAVIS, Calif., May 22, 2024 /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health by supporting the development and restoration of the immune system via the gut microbiome, announces additions to their advisory team: Dr. Katharine Knobil and Dr. David Pompliano. Additionally, Judy Gawlik Brown has joined the board, representing Manna Tree Partners, to help prepare the company's expansion into pharma.  Infinant Health recently announced their submission for ODD status and are augmenting their team with top-tier experts to s

      5/22/24 6:13:00 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • Belden Announces Appointment of Jay Wirts as EVP of Enterprise Solutions

      Appointment Demonstrates Belden's Commitment to Solutions Belden Inc. (NYSE:BDC) (the "Company"), a leading global supplier of network infrastructure solutions, today announced that Jay Wirts, President of Smart Buildings, has been appointed to the newly created position, Executive Vice President of Enterprise Solutions. "Jay is a transformational growth leader with a proven track record of operational success," said Belden President and CEO Ashish Chand. "With the creation of this new role, we are moving forward with our solution sales transformation for enterprise markets where multiple communications protocols based on copper, fiber and wireless technologies are coming together to so

      6/20/23 4:15:00 PM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • Belden Appoints Vivie "YY" Lee to Board of Directors

      Belden Inc. (NYSE:BDC), a leading global supplier of specialty networking solutions, announced that with immediate effect, it has appointed Vivie "YY" Lee as a Director and member of the Audit Committee. Ms. Lee brings over 30 years of experience in the software industry, including her experience in senior operational roles as a chief executive officer and chief operations officer. Ms. Lee most recently served as Chief Strategy Officer for Anaplan, a company specializing in subscription cloud-based business planning software. Her previous experience includes the CEO role at FirstRain, Inc., which was acquired by Ignite Technologies. She previously held management and product leadership pos

      3/31/23 7:30:00 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • SEC Form SC 13G filed by Belden Inc

      SC 13G - BELDEN INC. (0000913142) (Subject)

      11/8/24 10:29:30 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • SEC Form SC 13G filed by Belden Inc

      SC 13G - BELDEN INC. (0000913142) (Subject)

      10/7/24 11:37:08 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • SEC Form SC 13G/A filed by Belden Inc (Amendment)

      SC 13G/A - BELDEN INC. (0000913142) (Subject)

      2/13/24 5:00:45 PM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • Belden Reports First Quarter 2025 Results

      Belden Inc. (NYSE:BDC) ("Belden" or the "Company"), a leading global supplier of complete connection solutions, today reported fiscal first quarter results for the period ended March 30, 2025. First Quarter 2025 Highlights Revenues of $625 million, up 17% y/y and up 11% y/y organically GAAP EPS of $1.27, up 41% y/y Adjusted EPS of $1.60, up 29% y/y Repurchased 0.8 million shares for $85 million during the quarter, and 1.0 million shares for $100 million year-to-date through April 30, 2025 "Thanks to the efforts of our team, Belden had a strong start to the year with revenues up 17%, combined with expanding margins," said Ashish Chand, President and CEO of Belden. "Demand remains

      5/1/25 7:30:00 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • Belden earns an impressive spot in the "Great Place to Work" Canada 2025 ranking

      Awarded Most Trusted Executive Team badge and named among nation's best workplaces Belden Inc. (NYSE:BDC), a leading global provider of complete connection solutions, has been recognized with dual honors by Great Place to Work® Canada. This recognition is based on the feedback of Canadian employees surveyed, highlighting Belden's commitment to creating an exemplary workplace culture. Belden proudly secured a place on the prestigious "Best Workplaces with Most Trusted Executive Teams 2025" list and was also celebrated as the #44 Best Workplace in Canada for companies with 100-999 employees. These accolades are a testament to the trust and confidence placed in Belden's leadership, known for

      4/30/25 9:00:00 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • Belden Names Three Finalists for the Joseph C. Belden Innovation Award

      The winner of the 2nd annual award will be announced on June 17 Belden Inc. (NYSE:BDC), a leading global provider of complete connection solutions is pleased to announce that three companies have been selected as finalists for the 2nd annual Joseph C. Belden Innovation Award. The three finalists were selected from a highly competitive field of submissions by a panel of industry expert judges. Entries were evaluated on such criteria as level of innovation, business value and sustainability (environmental, social or governance) impact. Fellow innovators and thought leaders will explore the disruptive trends that are shaping the industry while honoring the 2025 Joseph C. Belden Innovation Aw

      4/22/25 9:00:00 AM ET
      $BDC
      Telecommunications Equipment
      Industrials

    $BDC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Strategy & Technology Bhadra Hiran was granted 5,548 units of Common Stock Holding, increasing direct ownership by 27% to 25,900 units (SEC Form 4)

      4 - BELDEN INC. (0000913142) (Issuer)

      3/28/25 2:13:07 PM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • EVP, Automation Solutions Lieser Brian sold $77,987 worth of shares (771 units at $101.15), decreasing direct ownership by 2% to 37,405 units (SEC Form 4)

      4 - BELDEN INC. (0000913142) (Issuer)

      3/19/25 11:01:25 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • SVP, Strategy & Technology Bhadra Hiran covered exercise/tax liability with 804 units of Common Stock Holding, decreasing direct ownership by 4% to 20,352 units (SEC Form 4)

      4 - BELDEN INC. (0000913142) (Issuer)

      3/17/25 4:36:00 PM ET
      $BDC
      Telecommunications Equipment
      Industrials

    $BDC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vertical Research initiated coverage on Belden with a new price target

      Vertical Research initiated coverage of Belden with a rating of Buy and set a new price target of $110.00

      7/23/24 6:21:26 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • Belden downgraded by Fox Advisors

      Fox Advisors downgraded Belden from Overweight to Equal Weight

      10/13/23 9:09:17 AM ET
      $BDC
      Telecommunications Equipment
      Industrials
    • UBS initiated coverage on Belden with a new price target

      UBS initiated coverage of Belden with a rating of Buy and set a new price target of $115.00

      9/27/23 7:58:01 AM ET
      $BDC
      Telecommunications Equipment
      Industrials